Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hybridon

Executive Summary

Antisense firm raises "an aggregate of $20 mil." in two private sales of convertible preferred stock to U.S. and foreign investors. In addition, Hoffmann-La Roche took a $4 mil. equity position in the company. On Feb. 4, Roche signed an agreement to fund Hybridon research on hepatitis B and C and human papilloma virus, a deal that also involved an equity purchase ("The Pink Sheet" Feb. 15, 1992, T&G-7). Hybridon says it "has completed and expects to announce a second partnership with a multinational pharmaceutical company" and the "total value of the two collaborations" will be over $50 mil.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022431

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel